Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Higher Keytruda Sales To Drive Merck's Q1?

08:00am, Wednesday, 24'th Apr 2024
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates.
As an investor with significant positions in equities, I am an optimist. However, it's important to be realistic at the same time.
Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart
CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.

3 Dow Stocks to Buy Now: Q2 Edition

03:17pm, Tuesday, 16'th Apr 2024
Let's be real – the narrative for Dow stocks to buy now tends to be one of relative safety. What are the chances that the 30 companies of the Dow Jones Industrial Average will be the most exciting i
Big pharma stocks, on balance, have been trading at a discount relative to the broader market for decades. Merck, a tier 1 U.S. pharmaceutical company, has been breaking out of this trend in 2024.
Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We

1 New Green Flag for Moderna and Merck Stock

08:45am, Friday, 12'th Apr 2024
Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.
In the closing of the recent trading day, Merck (MRK) stood at $126.15, denoting a -0.47% change from the preceding trading day.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Most people consider retirement one of the most important events to prepare for. Focusing on long-term investments, preferably with strong dividend yields, is a great way to get started.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE